Insider Trading Alert - UHS, BRO And LLY Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 11, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $332.85 to $17,302,509.00.

Highlighted Stocks Traded by Insiders:

Universal Health Services (UHS) - FREE Research Report

Osteen Debra K, who is Senior Vice President at Universal Health Services, sold 11,305 shares at $131.28 on June 11, 2015. Following this transaction, the Senior Vice President owned 88,440 shares meaning that the stake was reduced by 11.33% with the 11,305-share transaction.

The shares most recently traded at $131.11, down $0.17, or 0.13% since the insider transaction. Historical insider transactions for Universal Health Services go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 3,214
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 10,914
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 10,914

The average volume for Universal Health Services has been 725,900 shares per day over the past 30 days. Universal Health Services has a market cap of $12.1 billion and is part of the health care sector and health services industry. Shares are up 18.94% year-to-date as of the close of trading on Thursday.

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The stock currently has a dividend yield of 0.3%. The company has a P/E ratio of 22.8. Currently, there are 12 analysts who rate Universal Health Services a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UHS - FREE

TheStreet Quant Ratings rates Universal Health Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Universal Health Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Brown & Brown (BRO) - FREE Research Report

Strianese Anthony T, who is Pres. Wolesale Brokerage Div. at Brown & Brown, sold 3,000 shares at $32.96 on June 11, 2015. Following this transaction, the Pres. Wolesale Brokerage Div. owned 15,659 shares meaning that the stake was reduced by 16.08% with the 3,000-share transaction.

The shares most recently traded at $33.35, up $0.39, or 1.17% since the insider transaction. Historical insider transactions for Brown & Brown go as follows:

  • 4-Week # shares sold: 21,884
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 21,884
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 21,884

The average volume for Brown & Brown has been 723,900 shares per day over the past 30 days. Brown & Brown has a market cap of $4.7 billion and is part of the financial sector and insurance industry. Shares are up 1.58% year-to-date as of the close of trading on Thursday.

Brown & Brown, Inc. markets and sells insurance products and services primarily in the United States, as well as in London, Bermuda, and the Cayman Islands. The stock currently has a dividend yield of 1.33%. The company has a P/E ratio of 23.0. Currently, there are 7 analysts who rate Brown & Brown a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BRO - FREE

TheStreet Quant Ratings rates Brown & Brown as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, notable return on equity, increase in stock price during the past year and growth in earnings per share. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Brown & Brown Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 210,000 shares at $82.39 on June 11, 2015. Following this transaction, the 10% Owner owned 129.6 million shares meaning that the stake was reduced by 0.16% with the 210,000-share transaction.

The shares most recently traded at $84.14, up $1.75, or 2.08% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 830,200
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 1.6 million
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 1.7 million

The average volume for Eli Lilly and has been 4.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $92.3 billion and is part of the health care sector and drugs industry. Shares are up 25.51% year-to-date as of the close of trading on Thursday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The stock currently has a dividend yield of 2.4%. The company has a P/E ratio of 40.6. Currently, there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing